Archive for February 2026
Journal of Clinical Medicine: Likelihood of Blood Culture Positivity Using SeptiCyte RAPID
Abstract Background: Early diagnosis and identification of causative pathogens using blood culture in patients suspected of blood stream infection (BSI) and sepsis are critical for improving patient outcomes through earlier and more targeted treatment. There is a need for tools that can guide the use of microbiologic diagnostics, especially where resources are limited, such as…
Read MoreImmunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
Study supports utility of host-response testing in febrile neutropenia patients with haematological malignancies which may be the only indication of severe underlying infections SEATTLE and BRISBANE, Australia, Feb. 25, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new study demonstrating…
Read MoreDiagnostic accuracy of septicyte rapid to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at icu admission
Download the paper as a PDF Abstract Objectives The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission Design This is an observational,…
Read MoreImmunexpress Announces Publication Showing SeptiCyte RAPID® Identifies Septic Patients Most Likely to Have Positive Blood Cultures
Publication highlights strong association between a patient’s sepsis risk and likelihood of positive cultures, with SeptiCyte RAPID results just 90 minutes after a blood draw SEATTLE and BRISBANE, Australia, Feb. 12, 2026 /PRNewswire/ — Immunexpress, a molecular diagnostics company focused on improving outcomes for patients with suspected sepsis, today announced the publication of a new multi-center…
Read More